LYEL: Lyell Immunopharma Inc Net earnings per share (EPS TTM)

Lyell Immunopharma, Inc. (LYEL) - corporate logo

Lyell Immunopharma is currently developing its T-cell reprogramming platforms independently, limiting itself solely to clinical partnerships. This chart of net profit per share over the last 12 months helps track this trend, where the current level is -11.53. The business relies on a closed ecosystem of T-cell technologies; however, geopolitical tensions and sanctions are significantly hindering international research and the logistics of biomaterials.

LYEL Lyell Immunopharma Net earnings per share for the last 12 months (07/04/2022 - 11/18/2026)

Summary analytical data breakdowns for Lyell Pharma (LYEL)

Fundamental valuation:LYEL - Lyell Pharma
Flagship merchandise of Lyell Immunopharma Inc

Net income per share over 12 months measures the business's proportional earnings by distributing the aggregate financial result across the total number of securities to assess the actual efficiency of capital. By analyzing the rolling annual net income per share, an investor can discern the operational resilience of Lyell Immunopharma (LYEL), where the resource management discipline of biotech veterans determines the company's ability to fund breakthrough developments in cell therapy.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)